clinical_trials
'Groundbreaking Option' Approved for Rectal Cancer
Confidence86·multiple reportsImportance88NP-EVT-20261019-E6DD211
(MedPage Today) -- The FDA on Monday granted accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) to help select patients with operable rectal cancer potentially avoid surgery. The approval allows use in stage II/III patients with...
Read the original at the primary source
'Groundbreaking Option' Approved for Rectal Cancer
10/19/2026, 9:42:29 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —